In vitro assessment of drug resistance in Plasmodium falciparum in five States of India

Indian Journal of Medical Research

Volumn 135, Issue 4, 2012, Pages 494-499

  Anvikar, Anupkumar R ^a   Sharma, Bhawna ^b   Sharma, S K ^c   Ghosh, S K ^d   Bhatt, R M ^e   Kumar, Ashwani ^f   Mohanty, S S ^g   Pillai, C R ^a   Dash, A P ^a   Valecha, Neena ^a  

^a NATIONAL INSTITUTE OF MALARIA RESEARCH   (India)

^b Drugs for Neglected Diseases initiative   (India)

^c NIMR Field Unit   (India)

^d NIMR Field Unit   (India)

^e NIMR Field Unit   (India)

^f NIMR Field Unit   (India)

^g Desert Medicine Research Centre India   (India)

Author keywords

In vitro sensitivity; India; Malaria; Plasmodium falciparum

Indexed keywords

ARTESUNATE; CHLOROQUINE; DEETHYLAMODIAQUINE; MEFLOQUINE;

ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; CLINICAL ASSESSMENT; CROSS RESISTANCE; CRYOPRESERVATION; GENE MUTATION; GENOTYPE; IC 50; IN VITRO STUDY; INDIA; NONHUMAN; PLASMODIUM FALCIPARUM; WORLD HEALTH ORGANIZATION;

AMODIAQUINE; ARTEMISININS; BIOMARKERS, PHARMACOLOGICAL; CHLOROQUINE; DRUG RESISTANCE; HUMANS; INDIA; MEFLOQUINE; MEMBRANE TRANSPORT PROTEINS; MUTATION; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS;

EID: 84861948291     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Dash AP, Valecha N, Anvikar AR, Kumar A. Malaria in India: Challenges and opportunities. J Biosci 2008; 33: 583-592.
2. WHO expert committee on malaria, World Health Organ Tech Rep Ser, No. 892. 2000.
3. Baird JK. Effectiveness of antimalarial drugs. N Engl J Med 2005; 352: 1565-1577.
4. Sehgal PN, Sharma MID, Sharma SL, Gogai. Resistance to chloroquine in falciparum malaria in Assam state. J Commun Dis 1973; 5: 175-180.
5. Valecha N, Joshi H, Mallick PK, Sharma SK, Kumar A, Tyagi PK, et al. Low effcacy of chloroquine: Time to switch over to artemisinin-based combination therapy for falciparum malaria in India. Acta Trop 2009; 111: 21-28.
6. Dev V, Phookan S, Barman K. Therapeutic effcacies of antimalarial drugs in the treatment of uncomplicated, Plasmodium falciparum malaria in Assam, north-eastern India. Ann Trop Med Parasitol 2003; 97: 783-791.
7. Mohapatra PK, Namchoom NS, Prakash A, Bhattacharya DR, Goswami BK, Mahanta J. Therapeutic effcacy of anti-malarials in Plasmodium falciparum malaria in Indo-Myanmar border area of Arunachal Pradesh. Indian J Med Res 2003; 118: 71-76.
8. National Anti Malaria Programme. National drug policy on malaria. New Delhi: National Anti Malaria Programme, Directorate of Health Services, Government of India; 2005.
9. Vathsala PG, Pramanik A, Dhanasekaran S, Devi CU, Pillai CR, Subbarao SK, et al. Widespread occurrence of the Plasmodium falciparum chloroquine resistance transporter (Pfcrt) gene haplotype SVMNT in P. falciparum malaria in India. Am J Trop Med Hyg 2004; 7: 256-259.
10. Noedl H, Wernsdorfer WH, Miller RS, Wongsrichanalai C. Histidine-rich protein II: a novel approach to malaria drug sensitivity testing. Antimicrob Agents Chemother 2002; 46: 1658-1664.
11. World Health Organization. In vitro micro-test (Mark III) for the assessment of the response of Plasmodium falciparum to chloroquine, mefoquine, quinine, amodiaquine, sulfadoxine/pyrimethamine and artemisinin. Geneva: WHO; 2001.
12. Pradines B, Hovette P, Fusai T, Atanda HL, Baret E, Cheval P, et al. Prevalence of in vitro resistance to eleven standard or new antimalarial drugs among Plasmodium falciparum isolates from Pointe-Noire, Republic of the Congo. J Clin Microbiol 2006; 44: 2404-2408.
13. National Vector Borne Disease Control Programme, Directorate of Health Services, Government of India, 2010. Available from: http://nvbdcp.gov.in/TAC.html, assessed on July 31, 2010.
14. Usha Devi C, Pillai CR, Adak T, Sharma VP, Dwivedi SC. In vitro sensitivity of Indian isolates of Plasmodium falciparum to antimalarials. J Parasitic Dis 1996; 20: 177-180.
15. National Vector Borne Disease Control Programme. National Drug Policy on malaria. National Vector Borne Disease Control Programme, Directorate of Health Services, Government of India, 2010. Available from: http://www.nvbdcp.gov.in/, accessed on July 31, 2010.
16. Rehwagen C. WHO ultimatum on artemisinin monotherapy is showing results. BMJ 2006; 332: 1176.
17. Wongsrichanalai C, Lin K, Pang LW, Faiz MA, Noedl H, Wimonwattrawatee T, et al. In vitro susceptibility of Plasmodium falciparum isolates from Myanmar to antimalarial drugs. Am J Trop Med Hyg 2001; 65: 450-455.
18. Noedl H, Attlmayr B, Wernsdorfer WH, Kollaritsch H, Miller RS. Histidine rich protein 2 based malaria drug sensitivity assay for feld use. Am J Trop Med Hyg 2004; 71: 711-714.
19. Noedl H, Socheat D, Satimai W. Artemisinin- resistant malaria in Asia. N Engl J Med 2009; 361: 540-541.
20. Ahmed A, Bararia D, Vinayak S, Yameen M, Biswas S, Dev V, et al. Plasmodium falciparum isolates in India exhibit a progressive increase in mutations associated with sulfadoxine-pyrimethamine resistance. Antimicrob Agents Chemother 2004; 48: 879-889.
21. National Institute of Malaria Research. Guidelines for diagnosis and treatment of malaria in India. National Institute of Malaria Research, New Delhi, India, 2010. Available from: http://mrcindia.org/Guidelines_for_Diagnosis2010.pdf, accessed on March 22, 2012.